This content is from: Home

Pfizer’s arrival at patent cliff elicits concern from Congress

Pfizer yesterday became the latest major pharmaceutical manufacturer to see a leading drug patent expire with the introduction of generic versions of Lipitor - and now the company’s strategy for coping with the revenue loss has raised eyebrows in Congress

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.